

# Nisreen M A Okba

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3541730/publications.pdf>

Version: 2024-02-01

36  
papers

8,712  
citations

257450

24  
h-index

361022

35  
g-index

52  
all docs

52  
docs citations

52  
times ranked

19192  
citing authors

#	ARTICLE	IF	CITATIONS
1	Experimental and field investigations of exposure, replication and transmission of SARS-CoV-2 in pigs in the Netherlands. <i>Emerging Microbes and Infections</i> , 2022, 11, 91-94.	6.5	11
2	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. <i>Cell</i> , 2021, 184, 1188-1200.e19.	28.9	154
3	A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. <i>Nature Communications</i> , 2021, 12, 1715.	12.8	138
4	A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice. <i>European Journal of Immunology</i> , 2021, 51, 1774-1784.	2.9	30
5	Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 3189.	12.8	139
6	SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. <i>Journal of Infectious Diseases</i> , 2021, 223, 2020-2028.	4.0	28
7	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	64
8	Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	49
9	Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). <i>Nature Communications</i> , 2021, 12, 267.	12.8	601
10	Susceptibility of rabbits to SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2021, 10, 1-7.	6.5	133
11	A human monoclonal antibody blocking SARS-CoV-2 infection. <i>Nature Communications</i> , 2020, 11, 2251.	12.8	919
12	Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV. <i>Emerging Microbes and Infections</i> , 2020, 9, 1080-1091.	6.5	26
13	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <i>Science</i> , 2020, 369, 643-650.	12.6	1,104
14	Severe Acute Respiratory Syndrome Coronavirus 2-specific Antibody Responses in Coronavirus Disease Patients. <i>Emerging Infectious Diseases</i> , 2020, 26, 1478-1488.	4.3	1,389
15	An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. <i>Nature Communications</i> , 2020, 11, 3436.	12.8	321
16	SARS-CoV-2 is transmitted via contact and via the air between ferrets. <i>Nature Communications</i> , 2020, 11, 3496.	12.8	395
17	Serologic Detection of Middle East Respiratory Syndrome Coronavirus Functional Antibodies. <i>Emerging Infectious Diseases</i> , 2020, 26, 1024-1027.	4.3	16
18	Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 827-838.	9.1	125

#	ARTICLE	IF	CITATIONS
19	Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. <i>Science</i> , 2020, 368, 1012-1015.	12.6	802
20	Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Seropositive Camel Handlers in Kenya. <i>Viruses</i> , 2020, 12, 396.	3.3	16
21	Phenotype and kinetics of SARS-CoV-2 specific T cells in COVID-19 patients with acute respiratory distress syndrome. <i>Science Immunology</i> , 2020, 5, .	11.9	851
22	Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein. <i>Emerging Microbes and Infections</i> , 2019, 8, 1593-1603.	6.5	29
23	Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections. <i>Emerging Infectious Diseases</i> , 2019, 25, 1868-1877.	4.3	80
24	Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus. <i>Emerging Infectious Diseases</i> , 2019, 25, 1878-1883.	4.3	16
25	Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors. <i>Journal of Virology</i> , 2019, 93, .	3.4	33
26	Zika Virus Infection Induces Elevation of Tissue Factor Production and Apoptosis on Human Umbilical Vein Endothelial Cells. <i>Frontiers in Microbiology</i> , 2019, 10, 817.	3.5	22
27	Lack of Middle East Respiratory Syndrome Coronavirus Transmission in Rabbits. <i>Viruses</i> , 2019, 11, 381.	3.3	9
28	Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. <i>Emerging Microbes and Infections</i> , 2019, 8, 516-530.	6.5	99
29	MERS-CoV in Camels but Not Camel Handlers, Sudan, 2015 and 2017. <i>Emerging Infectious Diseases</i> , 2019, 25, 2333-2335.	4.3	21
30	Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection. <i>Science Advances</i> , 2018, 4, eaas9667.	10.3	66
31	Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels. <i>One Health</i> , 2018, 5, 65-68.	3.4	39
32	MERS-coronavirus: From discovery to intervention. <i>One Health</i> , 2017, 3, 11-16.	3.4	43
33	Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches. <i>Current Opinion in Virology</i> , 2017, 23, 49-58.	5.4	60
34	A poxvirus-based vaccine reduces virus excretion after MERS coronavirus infection in dromedary camels. <i>International Journal of Infectious Diseases</i> , 2016, 45, 421-422.	3.3	0
35	An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. <i>Science</i> , 2016, 351, 77-81.	12.6	216
36	Two-Component Spike Nanoparticle Vaccine Protects Macaques from SARS-CoV-2 Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0